Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis is a paper indexed in PICO Portal from OpenAlex.

How many citations does Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis have?

Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis has 58 citations in the OpenAlex counts PICO Portal stores.

When was Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis published?

Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis has 2022 year in the PICO Portal index.

What is the open-access status of Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis?

Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis has hybrid oa status in the PICO Portal index.

What is the DOI of Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis?

The DOI for Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis is on the source record.

What is the PMID of Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis?

The PMID for Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis is on the source record.

What is the OpenAlex record for Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis?

The OpenAlex for Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis is on the source record.